A Comparative Analysis of SARS-CoV-2 Antivirals Characterizes 3CL(pro) Inhibitor PF-00835231 as a Potential New Treatment for COVID-19

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent of coronavirus disease 2019 (COVID-19). There is a dire need for novel effective antivirals to treat COVID-19, as the only approved direct-acting antiviral to date is remdesivir, targeting the viral polymerase comp...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Virol
Egile Nagusiak: de Vries, Maren, Mohamed, Adil S., Prescott, Rachel A., Valero-Jimenez, Ana M., Desvignes, Ludovic, O’Connor, Rebecca, Steppan, Claire, Devlin, Joseph C., Ivanova, Ellie, Herrera, Alberto, Schinlever, Austin, Loose, Paige, Ruggles, Kelly, Koralov, Sergei B., Anderson, Annaliesa S., Binder, Joseph, Dittmann, Meike
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society for Microbiology 2021
Gaiak:
Vaccines and Antiviral Agents
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8139662/
https://ncbi.nlm.nih.gov/pubmed/33622961
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.01819-20
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak